<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="Research Paper"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of Pharmacy and Health Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPHR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2321-3647</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPHR11140004</article-id>
      <title-group>
        <article-title>Molecular Mechanisms In the Pathogenesis of Diabetic Nephropathy: Historical Development, Intracellular Signalling Pathways, Molecular Targets and Contemporary Therapeutic Strategies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mehta</surname>
            <given-names>Devansh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Independent Researcher and Scientific Writer, Meerut, Uttar Pradesh, India., 2\. Historical development of diabetic nephropathy research, ### 3\. Pathophysiology of diabetic nephropathy, This metabolic disturbance activates several biochemical pathways, resulting in:, Hyperglycaemia also promotes mitochondrial dysfunction and abnormal cellular energy metabolism., ### 3.2 Glomerular hyperfiltration, ### 3.3 Glomerular filtration barrier injury, ### 3.5 Tubulointerstitial injury</aff>
      <pub-date pub-type="epub" iso-8601-date="2026-11-16">
        <month>11</month>
        <day>16</day>
        <year>2026</year>
      </pub-date>
      <volume>14</volume>
      <issue>11</issue>
      <fpage>43</fpage>
      <lpage>73</lpage>
      <abstract>
        <p>Diabetic nephropathy (DN), increasingly described within the broader clinical framework of diabetic kidney disease (DKD), represents a major microvascular complication of diabetes mellitus and a leading contributor to chronic kidney disease and end-stage kidney failure worldwide. Its pathogenesis involves complex interactions among chronic hyperglycaemia, haemodynamic abnormalities, oxidative stress, inflammatory mediators, mitochondrial dysfunction, endothelial injury, podocyte damage and progressive extracellular matrix accumulation. Historically, the understanding of DN has evolved from morphological descriptions of glomerulosclerosis to the identification of hyperfiltration, renin–angiotensin–aldosterone system activation and multiple intracellular signalling networks. This review examines the historical development and molecular basis of DN, emphasising advanced glycation end-products and receptor for advanced glycation end-products signalling, protein kinase C activation, polyol and hexosamine pathways, transforming growth factor-β/Smad signalling, nuclear factor-κB, mitogen-activated protein kinases, phosphatidylinositol-3-kinase/Akt/mTOR, AMP-activated protein kinase, Nrf2/Keap1, Wnt/β-catenin and NLRP3 inflammasome activation. Particular attention is given to podocyte dysfunction, glomerular endothelial abnormalities, tubular metabolic stress, epigenetic regulation and renal fibrosis. Contemporary therapeutic strategies, including renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, are evaluated alongside landmark clinical trials and emerging molecular interventions. The review also discusses integrated treatment approaches, biomarker-based risk stratification and future therapeutic directions. Understanding the convergence of metabolic, haemodynamic and inflammatory pathways is essential for developing individualised, evidence-based interventions capable of delaying renal disease progression and improving long-term cardiorenal outcomes.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Diabetic kidney disease</kwd>
        <kwd>diabetic nephropathy</kwd>
        <kwd>AGE–RAGE signalling</kwd>
        <kwd>glomerular hyperfiltration</kwd>
        <kwd>podocytopathy</kwd>
        <kwd>mitochondrial oxidative stress</kwd>
        <kwd>TGF-β/Smad pathway</kwd>
        <kwd>NLRP3 inflammasome</kwd>
        <kwd>renal fibrogenesis</kwd>
        <kwd>cardiorenal pharmacotherapy.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
